Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Ute Hoch et al.|Cancer Discovery|2020Cited by 239
Supplementary Appendix from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0
Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0